방광암세포주의 항암제 반응에 대한 in vivo Hollow Fiber Assay = In vivo Hollow Fiber Assay for Anticancer Drugs' Responsiveness in a Bladder Cancer Model

다국어 초록 (Multilingual Abstract)

Purpose: The National Cancer Institute(NCI)'s Hollow Fiber Assay(HFA) is currently used as an in vivo screening model to quantitatively define anticancer activity. To investigate the use of HFA in a bladder cancer model, we conducted in vitro and in vivo experiments with several anticancer drugs in nude mice.
Materials and Methods: The human bladder cancer cell lines(CRL2742, 253JP, SW1710, HTB9) were cultured both in vitro and in vivo in polyvinylidene fluoride(PVDF) hollow fibers. The fibers were implanted intraperitoneally(ip) and subcutaneously(sc) into female athymic nude mice(C57BL/6), and the mice were then treated with gemcitabine 120 mg/kg(bolus), cisplatin(3mg/kg), paclitaxel(15mg/kg) or vehicle only (control) for 4-consecutive days. After 6 days, the fibers were retrieved and the viable cell density was analyzed by MTT assay.
Results: The difference between in vitro and in vivo growth was not significant for the CRL2742, 253J-P and SW1710 cell lines; the difference between the ip and sc fibers was also not significant in the CRL2742, SW1710 and HTB9 cell lines. After drug treatment, the percent of growth inhibition revealed constant and effective anticancer activities for the 3 individual drugs.
Conclusions: This study demonstrates the possibility of measuring and quantifying the anticancer effect with using in vivo hollow fiber assay in a bladder cancer model. (Korean J Urol 2008;49:392-397)

다국어 초록 (Multilingual Abstract)

Purpose: The National Cancer Institute(NCI)'s Hollow Fiber Assay(HFA) is currently used as an in vivo screening model to quantitatively define anticancer activity. To investigate the use of HFA in a bladder cancer model, we conducted in vitro and in vivo experiments with several anticancer drugs in nude mice.
Materials and Methods: The human bladder cancer cell lines(CRL2742, 253JP, SW1710, HTB9) were cultured both in vitro and in vivo in polyvinylidene fluoride(PVDF) hollow fibers. The fibers were implanted intraperitoneally(ip) and subcutaneously(sc) into female athymic nude mice(C57BL/6), and the mice were then treated with gemcitabine 120 mg/kg(bolus), cisplatin(3mg/kg), paclitaxel(15mg/kg) or vehicle only (control) for 4-consecutive days. After 6 days, the fibers were retrieved and the viable cell density was analyzed by MTT assay.
Results: The difference between in vitro and in vivo growth was not significant for the CRL2742, 253J-P and SW1710 cell lines; the difference between the ip and sc fibers was also not significant in the CRL2742, SW1710 and HTB9 cell lines. After drug treatment, the percent of growth inhibition revealed constant and effective anticancer activities for the 3 individual drugs.
Conclusions: This study demonstrates the possibility of measuring and quantifying the anticancer effect with using in vivo hollow fiber assay in a bladder cancer model. (Korean J Urol 2008;49:392-397)

참고문헌 (Reference)

1 Decker S, "The hollow fibre model in cancer drug screening: the NCI experience" 40 : 821-826, 2004

2 Bridges EM, "The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors" 149 : 103-111, 2006

3 van Moorsel CJ, "Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice" 35 : 808-814, 1999

4 Braakhuis BJ, "Schedule-dependent antitumor effect of gemcitabine in in vivo model system" 22(4 suppl 11) : 42-46, 1995

5 Wells RS, "Role of anchorage in the expression of tumorigenicity of untransformed mouse cell lines" 69 : 415-423, 1982

6 Shnyder SD, "Reducing the cost of screening novel agents using the hollow fibre assay" 26 : 2049-2052, 2006

7 Havaleshko DM, "Prediction of drug combination chemosensitivity in human bladder cancer" 6 : 578-586, 2007

8 Gorelik E, "Microencapsulated tumor assay: new short-term assay for in vivo evaluation of the effects of anticancer drugs on human tumor cell lines" 47 : 5739-5747, 1987

9 Shipley LA, "Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs" 20 : 849-855, 1992

10 Peters GJ, "Interaction between cisplatin and gemcitabine in vitro and in vivo" 22(4 suppl 11) : 72-79, 1995

11 Peterson JK, "Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development" 40 : 837-844, 2004

12 Hollingshead MG, "In vivo cultivation of tumor cells in hollow fibers" 57 : 131-141, 1995

13 Leong CO, "In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles" 3 : 1565-1575, 2004

14 Alami N, "In vitro and in vivo activity of C1311 and paclitaxel in three cancer tumor models" 2004 : 1069-1070, 2004

15 Casciari JJ, "Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model" 86 : 1846-1852, 1994

16 McMahon J, "Feasibility of cellular microencapsulation technology for evaluation of anti-human immunodeficiency virus drugs in vivo" 82 : 1761-1765, 1990

17 Jonsson E, "Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow- fibre model in rats" 46 : 493-500, 2000

18 Hovstadius P, "Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines" 15 : 63-70, 2004

19 Hassan S, "Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo" 55 : 47-54, 2005

20 Lee KH, "Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening" 37 : 190-200, 2005

21 Suggitt M, "Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo" 10 : 6677-6685, 2004

22 Sadar MD, "Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence" 1 : 629-637, 2002

23 Phillips RM, "Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs" 58 : 4263-4266, 1998

24 Hollingshead MG, "A potential role for imaging technology in anticancer efficacy evaluations" 40 : 890-898, 2004

25 Suggitt M, "50 years of preclinical anticancer drug screening: empirical to target-driven approaches" 11 : 971-981, 2005